Which nonpharmacologic methods can be used to decrease blood pressure select all that apply

1. Chobanian AV, Bakris GL, Black HR, et al. for the National Heart, Lung, and Blood Institute. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 1206–1252. [PubMed] [Google Scholar]

2. Centers for Disease Control and Prevention. High blood pressure. www.cdc.gov/bloodpressure/. Accessed March 21, 2009.

3. Lloyd-Jones D, Adams R, Carnethon M, et al. for the Writing Group Members. Heart Disease and Stroke Statistics 2009 Update: a Report from the American Heart Association Staistics Committee and Stroke Statistics Subcommittee. Circulation. 2009; 119: e21–e181. [PubMed] [Google Scholar]

4. Alcocer L, Cueto L. Hypertension, a health economics perspective. Ther Adv Cardiovasc Dis. 2008; 2: 147–155. [PubMed] [Google Scholar]

5. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003; 289: 2534–2544. [PubMed] [Google Scholar]

6. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360: 1903–1913. [PubMed] [Google Scholar]

7. Spurgeon D. NIH promotes use of lower cost drugs for hypertension. BMJ. 2004; 328: 539. [PMC free article] [PubMed] [Google Scholar]

8. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002; 287: 1003–1010. [PubMed] [Google Scholar]

9. US Preventive Services Task Force. Screening for high blood pressure: US Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2007; 147: 783–786. [PubMed] [Google Scholar]

10. American Academy of Family Physicians. Recommendations for clinical preventive services: high blood pressure. www.aafp.org/online/en/home/clinical/exam/f-j.html. Accessed April 11, 2009.

11. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997; 157: 2413–2446. [PubMed] [Google Scholar]

12. Forman JP, Brenner BM. Hypertension and microalbuminuria: the bell tolls for thee. Kidney Int. 2006; 69: 22. [PubMed] [Google Scholar]

13. Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003; 289: 2083–2093. [PubMed] [Google Scholar]

14. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967; 202: 1028–1034. [PubMed] [Google Scholar]

15. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991; 265: 3255–3264. [PubMed] [Google Scholar]

16. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981–2997. [PubMed] [Google Scholar]

17. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359: 2414–2428. [Google Scholar]

18. Saklayen MG. Which diuretic should be used for the treatment of hypertension? Am Fam Physician. 2008; 78: 444–446. [PubMed] [Google Scholar]

19. Ernst ME, Carter BL, Basile JN. All thiazide-like diuretics are not chlorthalidone: putting the ACCOMPLISH study into perspective. J Clin Hypertens (Greenwich). 2009; 11: 5–10. [PMC free article] [PubMed] [Google Scholar]

20. Jackson EK. Diuretics. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed.Columbus, OH: McGraw-Hill Professional; 2005:737–770. [Google Scholar]

21. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA. 2003; 289: 2560–2572 Erratum: JAMA. 2003; 290: 197. [Google Scholar]

22. Pitt B, Zannad F, Remme WJ, et al. for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on the morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999; 341: 709–717. [Google Scholar]

23. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309–1321. [PubMed] [Google Scholar]

24. Hoffman BB. Therapy of Hypertension. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed.Columbus, OH: McGraw-Hill Professional; 2005:845–868. [Google Scholar]

25. Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure-lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2008;(4):CD003822. [PMC free article] [PubMed]

26. Powers B, Datta S, Oddone E. A cost-effectiveness analysis of ACE-inhibitors vs. angiotensin receptor blockers for the treatment of hypertension. Presented at the Health Service Research and Development Service 2009 national meeting, February 11–13, 2009; Baltimore, MD. Abstract 1049.

27. Yusuf S, Teo KK, Pogue J, et al. for the ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358: 1547–1559. [PubMed] [Google Scholar]

28. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007; 8: 190–198. [PubMed] [Google Scholar]

29. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007; 25: 217–226. [PubMed] [Google Scholar]

30. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008; 358: 2433–2446. [PubMed] [Google Scholar]

31. Neal B, MacMahon S, Chapman N; for the Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs results of prospectively designed overviews of randomised trials. Lancet. 2000; 355: 1955–1964. [PubMed] [Google Scholar]

32. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004; 364: 1684–1689. [PubMed] [Google Scholar]

33. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ. 1992; 304: 405–412. [PMC free article] [PubMed] [Google Scholar]

34. Wiysonge CS, Bradley H, Mayosi BM, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007;(1):CD002003. [PubMed]

35. Moser M, Setaro J. Resistant or difficult-to-control hypertension. N Engl J Med. 2006; 355: 385–392. [PubMed] [Google Scholar]

36. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008; 52: 1749–1757. [PubMed] [Google Scholar]

37. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007; 49: 839–845. [PubMed] [Google Scholar]

38. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension. 2004; 43: 518–524. [PubMed] [Google Scholar]

Page 2

Classification and Management of BP for Adults